Interim safety results from TRUST, a global open-label study of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC)

被引：3
|
作者：
Ardizzoni, Andrea
Razis, Evangelia
Lichinitser, Mikhail
Yilmaz, Ugur
Grigorescu, Alexandru C.
Morero, Jose Luis
Skrickova, Jana
Cervantes, Guadalupe
Gottfried, Maya
Van Meerbeeck, Jan
机构：
[1] Univ Parma, Parma, Italy
[2] Hygeia Hosp, Athens, Greece
[3] NN Blochin Russian Oncol Res Ctr, Moscow, Russia
[4] Dokuz Eylu Univ, Med Fac, Izmir, Turkey
[5] Bucharest Oncol Inst, Bucharest, Romania
[6] Hosp Maria Ferrer, Buenos Aires, DF, Argentina
[7] Univ Hosp Brno, Brno, Czech Republic
[8] ISSSTE, Hosp Noviembre Ctr Medico, Mexico City, DF, Mexico
[9] Meir Sapir Med Ctr, Kefar Sava, Israel
[10] Univ Hosp, Ghent, Belgium
来源：
JOURNAL OF THORACIC ONCOLOGY | 2007年 / 2卷 / 08期
关键词：
D O I：
10.1097/01.JTO.0000283158.26734.bc
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S342 / S342
页数：1
相关论文
共 50 条
  • [41] Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)aEuro
    Joerger, M.
    von Pawel, J.
    Kraff, S.
    Fischer, J. R.
    Eberhardt, W.
    Gauler, T. C.
    Mueller, L.
    Reinmuth, N.
    Reck, M.
    Kimmich, M.
    Mayer, F.
    Kopp, H. -G.
    Behringer, D. M.
    Ko, Y. -D.
    Hilger, R. A.
    Roessler, M.
    Kloft, C.
    Henrich, A.
    Moritz, B.
    Miller, M. C.
    Salamone, S. J.
    Jaehde, U.
    ANNALS OF ONCOLOGY, 2016, 27 (10) : 1895 - 1902
  • [42] Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I-II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer
    Morgillo, Floriana
    Fasano, Morena
    Della Corte, Carminia Maria
    Sasso, Ferdinando Carlo
    Papaccio, Federica
    Viscardi, Giuseppe
    Esposito, Giovanna
    Di Liello, Raimondo
    Normanno, Nicola
    Capuano, Annalisa
    Berrino, Liberato
    Vicidomini, Giovanni
    Fiorelli, Alfonso
    Santini, Mario
    Ciardiello, Fortunato
    ESMO OPEN, 2017, 2 (02)
  • [43] Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study
    Ciuleanu, Tudor
    Stelmakh, Lilia
    Cicenas, Saulius
    Miliauskas, Skaidrius
    Grigorescu, Alexandru Calin
    Hillenbach, Carina
    Johannsdottir, Hrefna Kristin
    Klughammer, Barbara
    Esteban Gonzalez, Emilio
    LANCET ONCOLOGY, 2012, 13 (03): : 300 - 308
  • [44] Safety and efficacy results of a phase IV, open-label, multicenter, safety-monitoring study of icotinib in treating advanced non-small cell lung cancer (NSCLC): ISAFE study.
    Tan, Fenlai
    Gu, Aiqin
    Zhang, Yiping
    Jiao, Shun Chang
    Wang, Chang-Li
    He, Jintao
    Jia, Xueke
    Zhang, Li
    Peng, Jiewen
    Wu, Meina
    Ying, Kejing
    Wang, Junye
    Ma, Kewei
    Zhang, Shucai
    You, Changxuan
    Ding, Lieming
    Wang, Yinxiang
    Shen, Haijiao
    Wan, Jiang
    Sun, Yan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [45] Efficacy and Safety of Axitinib in Patients With Advanced Non-Small-Cell Lung Cancer: Results From a Phase II Study
    Schiller, Joan H.
    Larson, Timothy
    Ou, S-H. Ignatius
    Limentani, Steven
    Sandler, Alan
    Vokes, Everett
    Kim, Sinil
    Liau, Katherine
    Bycott, Paul
    Olszanski, Anthony J.
    von Pawel, Joachim
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (23) : 3836 - 3841
  • [46] Erlotinib Plus Anlotinib as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations: An Open-Label, Phase 2 Study
    Chu, T.
    Zhang, W.
    Zhang, B.
    Zhong, R.
    Shi, C.
    Zhang, X.
    Qian, J.
    Han, B.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S589 - S590
  • [47] THE EFFICACY AND THE SAFETY OF ERLOTINIB FOR THE PATIENTS WHO WERE DIAGNOSED WITH POSTOPERATIVE RECURRENCE OF NON-SMALL-CELL LUNG CANCER (NSCLC)
    Iwamaru, Arifumi
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1222 - S1222
  • [48] An open-label study on safety and tolerability of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer
    Okamoto, I.
    Udagawa, H.
    Kanda, S.
    Han, T. H.
    Lakatos, I.
    Zhang, F.
    Okubo, S.
    Scripture, C.
    Takeda, M.
    Akamatsu, H.
    Tamura, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [49] Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer
    Spigel, David R.
    Lin, Ming
    O'Neill, Vincent
    Hainsworth, John D.
    CANCER, 2008, 112 (12) : 2749 - 2755
  • [50] Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study
    Ranson, M.
    Reck, M.
    Anthoney, A.
    Hanauske, A. -R
    Dean, E.
    Melezinek, I.
    Klingelschmitt, G.
    Kletzl, H.
    Blatter, J.
    Twelves, C.
    ANNALS OF ONCOLOGY, 2010, 21 (11) : 2233 - 2239
12345